The Effect of Prucalopride on the Completion Rate and Polyp Detection Rate of Colon Capsule Endoscopies

Figures & data

Table 1 Bowel Preparation Regimens

Day	Standard Bowel Preparation + Prucalopride
−3	2x Polyethylene glycol 13.8 g sachet Normal diet 2 L water
−2	2x Polyethylene glycol 13.8 g sachet Normal diet 2 L water
−1	1 L Polyethylene glycol incl. ascorbic acid + 1 L water Clear liquid diet
0	Before capsule intake 1 L Polyethylene glycol incl. ascorbic acid +1 L water Clear liquid diet 1 tablet 2 mg prucalopride 45–60 minutes prior to ingestion^A After capsule intake Chewing gum Signal 1: 330 mL sulfate-based solution + 2–3 large glasses of water Signal 2: 330 mL sulfate-based solution + 2–3 large glasses of water Signal 3: 330 mL sulfate-based solution + 2–3 large glasses of water 1 Caffeine tablet, 200 mg and a small fatty snack, eg cheese. Signal 4: bisacodyl 10 mg, suppository

Notes: A, Only the prucalopride group received prucalopride, the rest of the bowel preparation was identical between the groups.

Abbreviations: g, gram; L, Liter; mg, milligram; mL, milliliter.

Table 2 Group Comparison

Variable	Standard Regimen (n=203)	Standard Regimen + Prucalopride (n=203)
Sex
Female	99 (48.8%)	96 (47.3%)
Male	104 (51.2%)	107 (52.7%)
Age
Mean, years	62.3	62.3

Table 3 Colon Capsule Endoscopy Outcomes

Variable	Standard Regimen (n=203)	Standard Regimen + Prucalopride (n=203)
Complete CCE	115 (56.7%)	152 (74.9%)
Conclusive CCE	153 (75.4%)	182 (89.7%)
Acceptable bowel preparation quality	116 (57.1%)	154 (75.9%)
Complete CCE transit	179 (88.2%)	193 (95.1%)
CCE average transit time^A	5h. 38 min.	3h. 30 min.
Polyp detection rate
Any size	163 (80.3%)	160 (78.8%)
>5 mm	131 (64.5%)	148 (72.9%)
>9 mm	73 (36.0%)	113 (55.7%)
Polyp count
Total	522	589
Mean, per individual	2.6	2.9

Notes: A, excluding incomplete CCE transits, standard n=179, standard plus prucalopride n=193.

Abbreviations: min, minutes; mm, millimeter.

Table 4 Leighton–Rex Bowel Preparation Grade Proportions per Colonic Segment

	Bowel Preparation Quality	Poor N (%)	Fair N (%)	Good N (%)	Excellent N (%)	Not Reported N (%)
Std.^A	Cecum	48 (23.7)	94 (46.3)	55 (27.1)	1 (0.5)	5 (2.5)
Std.+R^B		29 (14.3)	107 (52.7)	61 (30.1)	3 (1.5)	3 (1.5)
Std.	Right	37 (18.2)	89 (43.8)	72 (35.5)	2 (1.0)	3 (1.5)
Std.+R		27 (13.3)	102 (50.3)	69 (34.0)	3 (1.5)	2 (1.0)
Std.	Transverse	29 (14.3)	102 (50.3)	64 (31.5)	2 (1.0)	6 (3.0)
Std.+R		17 (8.4)	112 (55.2)	66 (32.5)	3 (1.5)	5 (2.5)
Std.	Left	24 (11.8)	96 (47.3)	75 (37.0)	1 (0.5)	7 (3.5)
Std.+R		17 (8.4)	84 (41.4)	93 (45.8)	3 (1.5)	6 (3.0)
Std.	Rectum	38 (18.7)	82 (40.4)	57 (28.1)	1 (0.5)	25 (12.3)
Std.+R		25 (12.3)	109 (53.7)	59 (29.1)	1 (0.5)	9 (4.4)

Notes: A, standard bowel preparation regimen, for details see Table 1. B, standard bowel preparation regimen plus prucalopride, for details see Table 1.

Abbreviations: Std., standard; R, Resolor.

Table 5 Multivariate Log Binomial Regression Model Estimating the Prevalence Ratio for Complete Colon Capsule Endoscopy

Variable	Prevalence Ratio	95% Confidence Interval
Standard bowel preparation	Reference
Standard bowel preparation + prucalopride	1.32	1.15; 1.53
Male sex	Reference
Female sex	1.00	0.88; 1.14
Age (years), continuous	0.99	0.99; 1.00

Table 6 Self-Reported Minor Adverse Events

Adverse Event	Standard Regimen (n=165)	Standard Regimen + Prucalopride (n=196)
Bloating	24 (14.5%)	32 (16.3%)
Abdominal pain	25 (15.2%)	29 (14.8%)
Rectal bleeding	6 (3.6%)	13 (6.6%)
Anal irritation/soreness	8 (4.8%)	5 (2.6%)
Nausea	9 (5.5%)	23 (11.7%)
Diarrhea	2 (1.2%)	11 (5.6%)
Headache	2 (1.2%)	11 (5.6%)
Fatigue	0 (0.0%)	10 (5.1%)